Published on
Professor Erika Lietzan participated on a panel at the 2025 Food and Drug Law Institute Annual Conference examining the top cases in 2024-2025 that will affect FDA. On the panel, she spoke about the impact of the Supreme Court’s 2024 Loper Bright decision on the agency. Professor Lietzen is currently completing a paper on this topic as well.